NASDAQ · SYRE
Spyre Therapeutics, Inc.
$96.02-$2.94 (-2.97%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.85% below the high.
Loading market information…
NASDAQ · GRNA · USD
Stock price, earnings
Quote as of Jul 21, 2023, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
GreenLight Biosciences Holdings’s quoted price sits in the lower half of its reported 52-week range, 94.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow GreenLight Biosciences Holdings’s reporting calendar.
THE COMPANY BEHIND THE TICKER
GreenLight Biosciences Holdings is a biotechnology firm focused on developing and commercializing ribonucleic acid (RNA) solutions. Its innovative products serve both the human health and agricultural industries. The company's human health portfolio includes mRNA vaccines and various therapeutic treatments, while its agricultural offerings feature RNA-based innovations designed to protect honeybees and defend crops. Established in 2008, GreenLight Biosciences Holdings is based in Medford, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:19 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Jun 30, 2021 |
| -$0.28 |
| $0.00 |
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$96.02-$2.94 (-2.97%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.85% below the high.
$0.68-$0.04 (-5.84%)
Rein Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.61% below the high.
$9.81+$0.39 (+4.14%)
AlloVir, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.38% below the high.
$4.97$0.00 (0.0%)
bluebird bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.62% below the high.
$0.78+$0.01 (+1.3%)
ERYTECH Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.01% below the high.
$0.70-$0.06 (-7.74%)
Magenta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.35% below the high.
$1.00-$0.03 (-2.91%)
Pluristem Therapeutics Inc.: Healthcare · Biotechnology.
$1.10$0.00 (0.0%)
Satsuma Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.39% below the high.
